Top 5 Schizophrenia Stories of 2018
The most-read schizophrenia-related stories on Psych Congress Network in 2018:
Anticipate some significant changes in the treatment of schizophrenia over the next 10 years, from a move toward coordinated specialty care to harnessing the power of social media to help identify symptoms sooner, said John M. Kane, MD.
Intra-Cellular Therapies, Inc. has submitted a New Drug Application to the US Food and Drug Administration for lumateperone, a investigational medicine with a novel mechanism of action for the treatment of schizophrenia.
A novel agent for the treatment of schizophrenia is producing promising results in efficacy and safety trials. Researchers from Intra-Cellular Therapies Inc., the developer of lumateperone, presented an overview of late-stage studies of the drug at Psych Congress 2018.
Does inflammation play a role in the pathophysiology of schizophrenia, and if so, is there a benefit from anti-inflammatory treatment?
The investigational olanzapine-samidorphan drug ALKS 3831 improved symptoms of schizophrenia, a study found.